Medelis

Medelis is a specialty oncology CRO that leverages deep therapeutic expertise and operational experience to guide biotech and pharma clients through complex cancer drug development. Its core value proposition is providing strategic, high-touch partnership from study design through execution, with notable capabilities in immunotherapy, study rescue, and facilitating U.S. market access for international sponsors. The company differentiates itself through its focused oncology knowledge, flexible resourcing, and cost-transparent model, aiming to deliver accurate data rapidly to inform critical development decisions.

Integrated oncology-focused CRO service model encompassing strategic drug development consulting, clinical trial design/management, and a specialized network of investigators. Expertise is centered on operational execution for complex trials, particularly in immunotherapy.

Competes directly with large, full-service global CROs (e.g., IQVIA, PPD, ICON) and other specialized, oncology-focused CROs. Differentiation is based on deep, exclusive oncology expertise, a flexible and partnership-driven service model, and cost transparency, positioning itself as an agile alternative to larger, less specialized providers.